Please use this identifier to cite or link to this item: https://doi.org/10.1038/modpathol.3800125
Title: Increased c-kit (CD117) expression in malignant mammary phyllodes tumors
Authors: Tse, G.M.K.
Putti, T.C. 
Lui, P.C.W.
Lo, A.W.I.
Scolyer, R.A.
Law, B.K.B.
Karim, R.
Lee, C.S.
Keywords: Breast
c-kit
CD117
Immunohistochemistry
Phyllodes tumor
Issue Date: Jul-2004
Citation: Tse, G.M.K., Putti, T.C., Lui, P.C.W., Lo, A.W.I., Scolyer, R.A., Law, B.K.B., Karim, R., Lee, C.S. (2004-07). Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Modern Pathology 17 (7) : 827-831. ScholarBank@NUS Repository. https://doi.org/10.1038/modpathol.3800125
Abstract: Mammary phyllodes tumors are uncommon stromal neoplasms, and are divided into benign, borderline and malignant groups basing on histologic criteria. While benign phyllodes tumors may recur, borderline phyllodes tumors show higher propensity to recur locally and rarely metastasize, and malignant phyllodes tumors show even higher chances of local recurrences or distant metastases. c-kit is a proto-oncogene that encodes a tyrosine kinase receptor (CD117) and is a marker for gastrointestinal stromal tumors (GIST). With the advent of therapeutic agent targeted at this receptor for GIST, we investigated 179 phyllodes tumors (101 benign, 50 borderline, 28 malignant) for c-kit expression using immunohistochemistry. The staining was compared to the degree of malignancy, and to the degree of stromal cellularity, mitotic activity, nuclear pleomorphism and stromal overgrowth. The overall positive rate for c-kit was 29% (52/178) and 17% (17/101), 24% (12/50) and 46% (13/28), respectively, for benign, borderline malignant and frank malignant phyllodes and the differences between all categories were significant (χ2 = 13.844, P=0.001). In mammary phyllodes tumors, there was increasing c-kit expression with increasing degree of malignancy, up to 46% in malignant cases. This provides strong evidence that c-kit receptor mediated tyrosine kinase involvement in the pathogenesis of phyllodes tumors, and the therapeutic agent, STI571, Glivec, may be a potentially useful drug for its management.
Source Title: Modern Pathology
URI: http://scholarbank.nus.edu.sg/handle/10635/131109
ISSN: 08933952
DOI: 10.1038/modpathol.3800125
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

50
checked on Jun 20, 2018

WEB OF SCIENCETM
Citations

41
checked on Jun 20, 2018

Page view(s)

5
checked on Feb 25, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.